2020-12-02

Camurus announces that Braeburn receives Complete Response Letter for Brixadi for opioid use disorder in the US

Camurus AB today announced that Camurus licensee Braeburn has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) regarding its new drug application (NDA) for Brixadi.

Read the full press release: https://www.camurus.com/

Acquisition of Scan Coin property

On April 18, 2017 the purchase deed was signed and Sandberg Development is now the owner of the property.

2017-05-18

Refurbishment of production facilities complete

One year after the reconstruction work started, the new production facilities were completed in March 2017.

2016-04-28

Refurbishment of production and office facilities

In March 2016 reconstruction and extension work started at our premises on Jägershillgatan 15 in Malmö. The first pa…

2016-01-14

Sandberg Development sponsor of Star for Life

From 2015 Sandberg Development is a sponsor of Star for Life, an educational/motivational programme, the aim of whic…

2016-01-07

Camurus's initial public offering a success

On Thursday December 3, 2015, Camurus started its first day of trading on Nasdaq Stockholm. The share price increase…